Списки наблюдения Идеи ProPicks на основе ИИ Фильтр Обозреватель данных Графики Сохраненная работа

X4 Pharmaceuticals Inc

NASDAQCM:XFOR

США / Здравоохранение / Биотехнологии

Обзор

Финансовая отчетность за 5 лет

Цена акций

0,31 USD


Key Metrics	Latest
Total Revenue	1,123 M
Adjusted EBITDA	-130,3 M
EBITDA Margin	-11.602,8%
Net Profit Margin	-8.411,3%
Total Assets	178,2 M
Total Debt	78,203 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	12 Months	Sep-23	Sep-24

Revenue	0.00	3.00	0.00	0.00	0.00	1.12	0.00	1.12
% Growth		NA	(1.00)	NA	NA			NA

Adjusted EBITDA	(47.70)	(59.52)	(74.85)	(87.57)	(107.10)	(130.30)	(81.97)	(105.16)
% Margin	NA	(19.84)	NA	NA	NA	(116.03)	NA	(93.64)

Adjusted EBIT	(47.80)	(59.87)	(75.35)	(88.08)	(107.52)	(130.89)	(82.32)	(105.69)
% Margin	NA	(19.96)	NA	NA	NA	(116.55)	NA	(94.11)

Adjusted Net Income	(49.50)	(62.01)	(81.48)	(94.24)	(101.17)	(94.46)	(82.04)	(75.33)
% Margin	NA	(20.67)	NA	NA	NA	(84.11)	NA	(67.08)

Adjusted Basic EPS	(4.29)	(3.09)	(3.16)	(1.48)	(0.57)	(0.46)	(0.48)	(0.38)

Подтверждающие расчеты

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Sep-24	Sep-23	Sep-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	0	3	0	0	0	1	0	1
% Growth	NA	NA	-100.0%	NA	NA			NA

Cost of Revenue	0	0	0	0	0	(0)	0	(0)
Gross Profit	0	3	0	0	0	1	0	1
% Revenue	NA	100.0%	NA	NA	NA	55.9%	NA	55.9%

Research and Development	(30)	(42)	(51)	(61)	(72)	(75)	(57)	(60)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(18)	(21)	(25)	(27)	(36)	(56)	(26)	(46)
Other Inc / (Exp)	(4)	0	(10)	(2)	8	117	1	110
Total Operating Exp	(52)	(63)	(85)	(90)	(100)	(15)	(81)	4

Operating Income	(52)	(60)	(85)	(90)	(100)	(14)	(81)	4
% Revenue	NA	-1985.6%	NA	NA	NA	-1270.8%	NA	390.5%

Interest Expense	(1)	(2)	(4)	(4)	(1)	(2)	(1)	(2)
Pre-tax Income	(53)	(62)	(89)	(94)	(101)	(17)	(82)	2
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Net Income to Company	(53)	(62)	(89)	(94)	(101)	(17)	(82)	2
% Margin	NA	-2071.0%	NA	NA	NA	-1492.3%	NA	211.1%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	(53)	(62)	(89)	(94)	(101)	(17)	(82)	2

Preferred Dividends	1	0	0	0	0	0	0	0
Other Adj.	(1)	0	(14)	(3)	0	0	0	0

Net Income to Common	(53)	(62)	(103)	(96)	(101)	(17)	(82)	2
% Margin	NA	-2071.0%	NA	NA	NA	-1492.3%	NA	211.1%

As Reported
Basic EPS (Continuing Ops)	(4.63)	(3.09)	(3.99)	(1.52)	(0.57)	(0.08)	(0.48)	0.01
Diluted EPS (Continuing Ops)	(4.63)	(3.09)	(3.99)	(1.52)	(0.57)	(0.08)	(0.48)	0.01

WA Basic Shares Out.	11.53	20.08	25.75	63.53	177.81	207.50	170.75	200.43
WA Diluted Shares Out.	11.53	20.08	25.75	63.53	177.81	207.67	170.75	200.61

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(53)	(62)	(89)	(94)	(101)	(17)	(82)	2
Addback: Net Interest Expense	1	2	4	4	1	2	1	2
Addback: Other Non Operating Expenses, Total	(0)	(0)	(0)	2	(8)	(12)	(1)	(5)
Addback: Depreciation & Amortization	0	0	0	1	0	1	0	1
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	10	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	4	0	0	(1)	0	(105)	0	(105)
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	1	0	0	0	0	0	0	0
Adjusted EBITDA	(48)	(60)	(75)	(88)	(107)	(130)	(82)	(105)
% Margin	NA	-1984.1%	NA	NA	NA	-11602.8%	NA	-9364.5%

Adjusted EBIT	(48)	(60)	(75)	(88)	(108)	(131)	(82)	(106)
% Margin	NA	-1995.8%	NA	NA	NA	-11654.9%	NA	-9411.0%

Adjusted Net Income Reconciliation
Net Income to Company	(53)	(62)	(89)	(94)	(101)	(17)	(82)	2
Addback: Unusual Items	4	0	10	(1)	0	(105)	0	(105)
Less: Tax Benefit of Unusual Items (26%)	(1)	(0)	(3)	0	0	27	0	27
Adjusted Net Income	(50)	(62)	(81)	(94)	(101)	(94)	(82)	(75)
% Margin	NA	-2067.0%	NA	NA	NA	-8411.3%	NA	-6707.8%

Ошибка загрузки

X4 Pharmaceuticals Inc

NASDAQCM:XFOR

США / Здравоохранение / Биотехнологии

Финансовая отчетность за 5 лет